SecBot SecBot
144 ·Filed Nov 2, 2026

ARQT

Arcutis Biotherapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed14d 7h ago SEC0001628280-26-068988
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The sale is a routine post-vesting disposition by an officer with no unusual size or timing. Monitor for any additional insider selling patterns in future filings.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$32.00
T+0 close · Nov 2, 2026 · via day close
Latest settled
−14.42%
T+5 · $27.39 · next T+20 in 15d
Vs SPY
−13.83%
α at T+5
Latest observation
−11.21%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $32.00entry
  2. T+1 · 13d ago +6.41%α +4.75% · $34.05
  3. T+5 · 7d ago −14.42%α −13.83% · $27.39
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Todd Watanabe, an officer of Arcutis Biotherapeutics, filed a Form 144 on November 2, 2026, indicating intent to sell 4,377 shares of common stock with an approximate market value of $139,466. The shares were acquired via restricted stock vesting on November 1, 2026. This is a routine sale following vesting, representing a small fraction of the company's $4.0B market cap.

Key Facts

  • Insider Todd Watanabe (officer) filed Form 144 to sell 4,377 shares of common stock.
  • Estimated value of proposed sale: $139,466.
  • Shares acquired via restricted stock vesting on November 1, 2026.
  • Proposed sale date: November 2, 2026.
  • Company market cap: $4.0B; sale represents ~0.0035% of market cap.
  • Recent insider activity (30 days): 1 sell totaling $127K.

Financial Impact

Proposed sale of 4,377 shares valued at $139,466, or ~0.0035% of market cap.

dilution

Risk Factors

  • Form 144 is an intent to sell; the actual sale may not occur.
  • No unusual signals from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001628280-26-068988
Document: 0001628280-26-068988-index.html0001628280-26-068988
Document: 0001628280-26-068988.txt0001628280-26-068988

Track record

34 reports on ARQT

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
  3. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
  4. Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  5. Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  6. Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
  7. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  8. Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  9. Nov 2, 202614d ago 144 Neutral 2/10 Viewing Entry $32.00 Now $27.15 −15.16% settles Feb 1
  10. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
Showing 10 of 34

US Market Status

Market Closed · Opens in 8h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026